Decreased TMIGD1 Aggravates Colitis and Intestinal Barrier Dysfunction via the BANF1-NF-κB Pathway in Crohn’s Disease

Investigators demonstrated that transmembrane and immunoglobulin domain-containing protein 1 (TMIGD1) maintained intestinal barrier integrity and inactivated inflammation, and was therefore a potential therapeutic target for Crohn’s’ disease.